Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Add To Watchlist

Recent & Breaking News (NYSE:BMY)

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

Business Wire April 27, 2015

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients

Business Wire April 24, 2015

Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America

Business Wire April 16, 2015

Ovid Therapeutics Appoints Dr. Jeremy Levin as Chief Executive Officer

Business Wire April 16, 2015

Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc.

Business Wire April 8, 2015

Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases

Business Wire April 6, 2015

Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28

Business Wire March 27, 2015

Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases

Business Wire March 24, 2015

Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3

Business Wire March 12, 2015

FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer

Business Wire March 4, 2015

Bristol-Myers Squibb Announces U.S. FDA Approval of an Additional Indication for Opdivo (nivolumab)

Business Wire March 4, 2015

Hepatitis C cure rate of 97 per cent announced in study of patients co-infected with HIV given 12-week combination treatment of daclatasvir and sofosbuvir in ALLY-2 trial

Canada NewsWire March 3, 2015

Bristol-Myers Squibb Announces Dividend

Business Wire March 2, 2015

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy® (ipilimumab) as Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence

Business Wire March 2, 2015

U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Business Wire February 27, 2015

ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir

Business Wire February 26, 2015

Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies

Business Wire February 26, 2015

48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation

Business Wire February 25, 2015

Bristol-Myers Squibb to Present at Cowen and Company Annual Global Health Care Conference

Business Wire February 24, 2015

Bristol-Myers Squibb Foundation Awards GRU Cancer Center Three-Year, $1.74M Grant to Address Lung Cancer Among Neediest Communities in Central Savannah River Area

Business Wire February 23, 2015